Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Pr....

Article · May 2017
DOI: 10.1001/jamapediatrics.2017.0602

CITATIONS
3

READS
141

20 authors, including:

Mikael Norman
Karolinska Institutet
224 PUBLICATIONS  5,403 CITATIONS

Lene Huusom
Copenhagen University Hospital Hvidovre
6 PUBLICATIONS  35 CITATIONS

Anna-Karin Edstedt Bonamy
Karolinska Institutet
88 PUBLICATIONS  1,522 CITATIONS

Liis Toome
Tallinn Children’s Hospital
25 PUBLICATIONS  63 CITATIONS

Some of the authors of this publication are also working on these related projects:

National Swedish Guidelines - Screening and treating postnatal hypoglycemia View project

EPICE European project: study on causes of death and decision-making in NICUs View project

All content following this page was uploaded by Mikael Norman on 24 October 2017.
The user has requested enhancement of the downloaded file.
Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants
Results From the EPICE Cohort
Mikael Norman, MD, PhD; Aurélie Piedvache, MSc; Klaus Berch, MD, PhD; Lene Drasbek Huusom, MD, PhD; Anna-Karin Edstedt Bonamy, MD, PhD; Elizabeth A. Howell, MD, MPP; Pierre-Henri Jarreau, MD, PhD; Rolf F. Maier, MD, PhD; Heili Varendi, MD, PhD; Ole Pryds, MD, PhD; Liis Toome, MD, PhD; Tom Weber, MD, DMSc; Emilia Wilson, RN, RM; Ano Van Heijst, MD, PhD; Marina Cuttini, MD, PhD; Jan Mazela, MD, PhD; Henrique Barros, MD, PhD; Patrick Van Reempts, MD, PhD; Elizabeth S. Draper, BSc(Hons), MPhil, PhD; Jennifer Zeitlin, MA, DSc; for the Effective Perinatal Intensive Care in Europe (EPICE) Research Group

IMPORTANCE Administration-to-birth intervals of antenatal corticosteroids (ANS) vary. The significance of this variation is unclear. Specifically, to our knowledge, the shortest effective administration-to-birth interval is unknown.

OBJECTIVE To explore the associations between ANS administration-to-birth interval and survival and morbidity among very preterm infants.

DESIGN, SETTING, AND PARTICIPANTS The Effective Perinatal Intensive Care in Europe (EPICE) study, a population-based prospective cohort study, gathered data from 19 regions in 11 European countries in 2011 and 2012 on 4594 singleton infants with gestational ages between 24 and 31 weeks, without severe anomalies and unexposed to repeated courses of ANS. Data were analyzed November 2016.

EXPOSURE Time from first injection of ANS to delivery in hours and days.

MAIN OUTCOMES AND MEASURES Three outcomes were studied: in-hospital mortality; a composite of mortality or severe neonatal morbidity, defined as an intraventricular hemorrhage grade of 3 or greater, cystic periventricular leukomalacia, surgical necrotizing enterocolitis, or stage 3 or greater retinopathy of prematurity; and severe neonatal brain injury, defined as an intraventricular hemorrhage grade of 3 or greater or cystic periventricular leukomalacia.

RESULTS Of the 4594 infants included in the cohort, 2496 infants (54.3%) were boys, and the mean (SD) gestational age was 28.5 (2.2) weeks and mean (SD) birth weight was 1213 (400) g. Mortality for the 662 infants (14.4%) unexposed to ANS was 20.6% (136 of 661). Administration of ANS was associated with an immediate and rapid decline in mortality, reaching a plateau with more than 50% risk reduction after an administration-to-birth interval of 18 to 36 hours. A similar pattern for timing was seen for the composite mortality or morbidity outcome, whereas a significant risk reduction of severe neonatal brain injury was associated with an intraventricular hemorrhage grade of 3 or greater or cystic periventricular leukomalacia.

CONCLUSIONS AND RELEVANCE Antenatal corticosteroids may be effective even if given only hours before delivery. Therefore, the infants of pregnant women at risk of imminent preterm delivery may benefit from its use.

Published online May 15, 2017.
Antenatal corticosteroids (ANS) reduce morbidity and mortality in preterm infants and are recommended for women at risk of delivery before 34 weeks’ gestation.\textsuperscript{1-5} Antenatal corticosteroids have been estimated to reduce infant mortality by 31%, respiratory distress syndrome by 34%, intraventricular hemorrhage by 46%, and necrotizing enterocolitis by 54%.\textsuperscript{4}

While there seems to be agreement that neonatal benefits are maximized when ANS are administered 24 hours to 7 days before delivery,\textsuperscript{4,6-13} less is known about other and narrower administration-to-birth intervals.\textsuperscript{5} In particular, to our knowledge, the latest point at which ANS can be effectively used is not known.\textsuperscript{3} Given favorable pharmacokinetics\textsuperscript{14} and rapid circulatory effects,\textsuperscript{15-18} ANS may be effective even hours before birth. At the other end of the administration-to-birth interval, some\textsuperscript{6-11} but not all\textsuperscript{12,13} studies suggest declining benefits from ANS if administered more than 7 days before preterm birth. Limitations in statistical power, varying exposures,\textsuperscript{5,19} and outcomes\textsuperscript{6-13} may contribute to such diverse results and interpretations.

Because the problem of timely prediction of preterm delivery remains unresolved,\textsuperscript{20} administration of ANS will continue to occur hours, days, or weeks before delivery. Therefore, a more detailed understanding of the importance of the administration-to-birth interval of ANS for infant outcome is needed. The objective of this study was to investigate associations between different administration-to-birth intervals of ANS in hours and morbidity and mortality in very preterm infants.

Methods

The Effective Perinatal Intensive Care in Europe (EPICE) cohort study is a population-based study on the use of evidence-based practices in very preterm births with less than 32 weeks’ gestation in 19 regions across 11 European countries, conducted in 2011 and 2012 (http://www.epiceproject.eu).\textsuperscript{21} Geographic and organizational diversity, feasibility, and sample size were accounted for when selecting regions. Inclusions occurred over a 12-month period except in France (6-month period). Ethics approval was obtained in each region, as required by national legislation. The European study was also approved by the French Advisory Committee on Use of Health Data in Medical Research (CCTIRS) and the French Commission for Data Protection and Liberties (CNIL). Informed parental consent (active or passive, depending on each participating country’s national legislations) was obtained; in some regions, consent requirements were waived by ethics boards for parents not included in the follow-up cohort (ie, stillbirths and neonatal deaths), as data were deidentified and from routine sources.

Study Population

From a total of 10 329 births, we excluded 2429 terminations of pregnancy and stillbirths, 126 infants with severe congenital anomalies, 2336 multiples, 300 infants born at 22 and 23 weeks’ gestational age (GA),\textsuperscript{22} 362 infants of mothers with missing data on date and time of ANS administration, and 182 infants of mothers who had received more than 1 course of ANS. A repeated course was defined as an interval between ANS injections exceeding 1 week. The final sample consisted of 4594 singleton live-births at 24 to 31 weeks’ GA (Figure 1). Administration of corticosteroids during pregnancy for indications other than preterm birth was not included in the study protocol.

Exposure

For each infant, information was collected on dates and times of the first ANS injection as well as the total number of injections. Questionnaires were also sent to the heads of the maternity units regularly managing 10 or more very preterm admissions annually. Most maternity units (123 of 135 [91.1%]) responded, and protocols for ANS, including type of drug, doses, and number and intervals of injections, were collected.

We defined our exposure as time from the first injection of ANS to delivery. We classified ANS exposure in 4 categories (no ANS, first injection <24 hours, first injection between 24 hours and 7 days, and first injection >7 days before birth) for descriptive analyses of the characteristics of women and newborns and for comparison with other studies.\textsuperscript{8} For more detailed analyses of associations between timing of ANS and outcome, we used administration-to-birth intervals as a continuous variable. We did not include information on 1 or more courses of ANS in our analysis.

Key Points

**Question** What is the shortest administration-to-birth interval of antenatal corticosteroids that promotes survival and decreases neonatal morbidity in very preterm infants?

**Findings** In a population-based cohort of 4594 European infants born before 32 weeks’ gestation, we found that in-hospital mortality was significantly reduced when antenatal corticosteroids had been administered only a few hours prior to delivery.

**Meaning** Encouraging administration of antenatal corticosteroids when delivery is very imminent could result in substantial survival and health gains for very preterm infants.

![Figure 1. Flowchart for Inclusions](http://www.epiceproject.eu)
several doses of ANS because of high collinearity between timing of ANS and number of doses; 866 of 1111 women (77.9%) receiving ANS less than 24 hours prior to delivery received only 1 dose.

For some women, we only had information on the date of ANS administration but not the time. This caused problems for our classifications when administration was within 2 days of delivery (204 of 1522 women [13.4%] delivering within 2 days). For a solution, we used multiple imputations chained equations to impute these data based on all variables in the study in addition to the time of delivery, date of administration, and number of injections received. We used 100 imputed data sets. Results are presented using imputed data.

Outcomes
Based on the evidence of the effects of ANS on preterm infants,1–8 the outcomes selected were in-hospital mortality, a composite of mortality or severe neonatal morbidity or both, or severe neonatal brain injury. In-hospital mortality was defined as death before discharge home. Severe neonatal morbidity was defined as an intraventricular hemorrhage grade of 3 or 4,2,4 cystic periventricular leukomalacia,2,5 stage 3, 4, or 5 retinopathy of prematurity,2,6 or severe necrotizing enterocolitis (assessed as need for surgery or peritoneal drainage; Bell stages2,7 were not routinely recorded in all regions) among infants discharged alive. Severe neonatal brain injury was defined as an intraventricular hemorrhage grade of 3 or 4, cystic periventricular leukomalacia, or both. We did not include bronchopulmonary dysplasia into our composite outcome because of regional variability in respiratory management and oxygen saturation targets have major effects on rates of bronchopulmonary dysplasia.2,8

Covariables
Covariables that could be potential confounders of the associations between timing of ANS and infant outcome were selected based on the literature4,6,29–32 and clinical knowledge. We included variables reflecting case mix (maternal age; parity; pregnancy complications, including preeclampsia, eclampsia, and hemolysis, elevated liver enzyme levels, low platelet count syndrome; preterm prelabor rupture of membranes; GA [defined as best assessment based on last menstrual period or antenatal ultrasonography, part of routine obstetric care in all regions]; smallness for gestational age [defined as birth weight less than the third and between the third and 10th centiles, based on customized intrauterine growth curves33]; and infant sex) and variables related to management of the delivery (birth at a level II neonatal unit; mode of delivery; and delivery on same day as admission to hospital). Preeclampsia was defined as hypertension after 20 weeks’ GA (blood pressure of 140/90 mm Hg or higher) and proteinuria with a protein level of 0.3 g/L or greater, and eclampsia was defined as hypertension associated with convulsions or coma. Preterm prelabor rupture of membranes was defined as spontaneous rupture of membranes 12 hours or more before onset of contractions.

Results
The most common ANS protocol was two 12-mg injections 24 hours apart (performed in 105 of 123 units [85.4%]), followed by two 12-mg injections 12 hours apart (performed in 13 units [10.6%]). Another 4 units (3.3%) used other protocols. Betamethasone was used in 97 units (78.9%), dexamethasone in 6 units (4.9%), and both in 19 units (15.4%) (eTable 1 in the Supplement).

Distribution of Administration-to-Birth Intervals
Fewer than half of included women (1871 of 4594 [40.7%]) received ANS 24 hours to 7 days before delivery, ie, by current standards, the administration-to-birth interval considered to be optimal. Many women received ANS closer to delivery (1111 [24.2%]) or did not receive ANS (662 [14.4%]) (Table 1). The cumulative distribution of administration-to-birth intervals are presented in eFigure 1 in the Supplement. Administration and timing of ANS varied across the 19 European regions (eFigure 2 in the Supplement).

Perinatal Characteristics by Timing of ANS
Variables reflecting population case mix and management of preterm delivery differed between ANS categories, with the exception of infant sex (Table I). In particular, women receiving ANS more than 7 days before delivery were more likely to have preterm prelabor rupture of membranes and a higher GA and to deliver in a level III unit. Of patients with missing data, 235
of 362 (64.9%) came from 3 of the 19 regions, reflecting difficulties in data collection. After adjustment on region, infants with missing information were more often born to mothers with preeclampsia, more often delivered with cesarean section, and less often born at level III units than infants in the study population (eTable 2 in the Supplement).

### Timing of ANS and Outcome

Using 4 categories of ANS timing, any ANS—irrespective of the administration-to-birth interval—was associated with lower infant mortality than no ANS, with the largest risk reduction for ANS administered 24 hours to 7 days before delivery (adjusted risk ratio, 0.5; 95% CI, 0.4-0.6). Antenatal corticosteroids administered 24 hours to 7 days before delivery was also associated with lower risks of mortality or severe neonatal morbidity and of lower risk for severe neonatal brain injury than no ANS (Table 2).

Increasing the resolution of the analyses by expressing the risk for our 3 outcomes as a continuous function of the administration-to-birth interval, ANS less than 12 hours before birth was associated with an immediate and rapid decline in mortality, followed by a slower risk reduction and reaching a plateau with more than 50% risk reduction after an administration-to-birth interval of 18 to 36 hours (Figure 2). A similar pattern for timing of ANS was seen for the composite outcome of mortality or severe neonatal morbidity (eFigure 3 in the Supplement), whereas a significant risk reduction of severe neonatal brain injury was associated with longer admin-

### Table 1. Characteristics of Very Preterm Infants by 4 ANS Administration-to-Birth Intervals

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>ANS Administration-to-Birth Interval, No. (%)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational age, mean (SD), wk</td>
<td>28.3 (2.3)</td>
<td>28.5 (2.2)</td>
</tr>
<tr>
<td>SGA, birth weight centiles</td>
<td>104 (15.7)</td>
<td>204 (18.4)</td>
</tr>
<tr>
<td>&lt;3</td>
<td>62 (9.4)</td>
<td>103 (9.3)</td>
</tr>
<tr>
<td>3-10</td>
<td>496 (74.9)</td>
<td>804 (72.4)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>383 (57.9)</td>
<td>608 (54.8)</td>
</tr>
<tr>
<td>Sex</td>
<td>279 (42.2)</td>
<td>503 (45.2)</td>
</tr>
<tr>
<td>Male</td>
<td>282 (47.6)</td>
<td>560 (51.6)</td>
</tr>
<tr>
<td>Female</td>
<td>310 (52.4)</td>
<td>524 (48.4)</td>
</tr>
<tr>
<td>Surfactant &lt;2 h after birth</td>
<td>565 (89.4)</td>
<td>888 (80.9)</td>
</tr>
<tr>
<td>No</td>
<td>67 (10.6)</td>
<td>209 (19.1)</td>
</tr>
<tr>
<td>Yes</td>
<td>330 (50.7)</td>
<td>625 (56.7)</td>
</tr>
<tr>
<td>Primiparous</td>
<td>321 (49.3)</td>
<td>477 (43.3)</td>
</tr>
<tr>
<td>Parity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiparous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preeclampsia/eclampsia/HELLP</td>
<td>580 (91.5)</td>
<td>972 (88.4)</td>
</tr>
<tr>
<td>No</td>
<td>54 (8.5)</td>
<td>127 (11.6)</td>
</tr>
<tr>
<td>Yes</td>
<td>67 (10.6)</td>
<td>209 (19.1)</td>
</tr>
<tr>
<td>PPROM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>330 (50.7)</td>
<td>625 (56.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>321 (49.3)</td>
<td>477 (43.3)</td>
</tr>
<tr>
<td>Mode of delivery onset</td>
<td>414 (63.6)</td>
<td>662 (60.1)</td>
</tr>
<tr>
<td>Spontaneous or induced</td>
<td>237 (36.4)</td>
<td>439 (39.9)</td>
</tr>
<tr>
<td>Cesarean section</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mode of delivery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal</td>
<td>312 (48.1)</td>
<td>450 (40.9)</td>
</tr>
<tr>
<td>Cesarean section</td>
<td>337 (51.9)</td>
<td>652 (59.2)</td>
</tr>
<tr>
<td>Delivery at level III unit*</td>
<td>283 (42.9)</td>
<td>379 (34.1)</td>
</tr>
<tr>
<td>No</td>
<td>376 (57.1)</td>
<td>731 (65.9)</td>
</tr>
<tr>
<td>Yes</td>
<td>237 (36.4)</td>
<td>439 (39.9)</td>
</tr>
<tr>
<td>Delivery on day of admission</td>
<td>203 (32.6)</td>
<td>605 (56.3)</td>
</tr>
<tr>
<td>No</td>
<td>419 (67.4)</td>
<td>469 (43.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>419 (67.4)</td>
<td>469 (43.7)</td>
</tr>
</tbody>
</table>

Abbreviations: ANS, antenatal corticosteroids; HELLP, hemolysis, elevated liver enzyme levels, low platelet count syndrome; PPROM, preterm prelabor rupture of membranes; SGA, smallness for gestational age.

* Level III neonatal units were defined using local definitions of level of care.
### Table 2. Risk Ratios for In-Hospital Infant Mortality, a Composite of Mortality or Severe Neonatal Morbidity, and Neonatal Brain Injury Associated With ANS Administration-to-Birth Intervals Among Singleton Infants Born Before 32 Weeks’ Gestational Age

<table>
<thead>
<tr>
<th>ANS Administration-to-Birth Interval</th>
<th>In-Hospital Mortality</th>
<th>In-Hospital Mortality or Severe Neonatal Morbidity&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Severe Neonatal Brain Injury&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No./Total No. (%)</td>
<td>RR (95% CI)</td>
<td>No./Total No. (%)</td>
</tr>
<tr>
<td>No ANS</td>
<td>136/661 (20.6)</td>
<td>1 [Reference]</td>
<td>1 [Reference]</td>
</tr>
<tr>
<td>&lt;24 h</td>
<td>117/1110 (10.5)</td>
<td>0.5 (0.4-0.6)</td>
<td>0.6 (0.5-0.7)</td>
</tr>
<tr>
<td>24 h-7 d</td>
<td>171/1871 (9.1)</td>
<td>0.4 (0.4-0.5)</td>
<td>0.5 (0.4-0.6)</td>
</tr>
<tr>
<td>&gt;7 d</td>
<td>89/950 (9.4)</td>
<td>0.5 (0.4-0.6)</td>
<td>0.7 (0.6-0.9)</td>
</tr>
</tbody>
</table>

Abbreviations: ANS, antenatal corticosteroids; RR, risk ratio.

<sup>a</sup> Severe neonatal morbidity includes intraventricular hemorrhage grade 3 or more, cystic periventricular leukomalacia, surgical necrotizing enterocolitis, or stage 3 or more retinopathy of prematurity.

<sup>b</sup> Severe neonatal brain injury includes intraventricular hemorrhage grade 3 or more, cystic periventricular leukomalacia, or both.

Adjusted for patient case mix (maternal age; parity; pregnancy complications, including preeclampsia, eclampsia, and hemolysis, elevated liver enzyme levels, low platelet count syndrome; preterm prelabor rupture of membranes; gestational age; small for gestational age; and infant sex) and factors related to management of the delivery (birth at a level III neonatal unit; mode of delivery; and delivery on same day as admission to hospital).
For all outcomes, the risk reduction associated with ANS was transient, with increasing mortality and risk for severe neonatal brain injury associated with ANS administration-to-birth intervals of 5 to 7 days or more.

The reference relative risk represents very preterm infants who were not exposed to ANS before birth. The curves for adjusted relative risks represent means and 95% CI bands. CPVL indicates cystic periventricular leukomalacia; IVH, intraventricular hemorrhage.
In a simulation of providing ANS for the 661 infants in the sample who did not receive ANS, our model predicted a 26% decrease in mortality if these infants received ANS at least 3 hours before delivery, a 37% decrease if they received ANS 3 to 5 hours before delivery, and a 51% decrease if they received ANS 6 to 12 hours before delivery (eTable 3 in the Supplement).

Discussion

Our findings suggest that infant mortality was rapidly and significantly reduced when ANS were administered only a few hours before delivery. Infant birth 12 hours following ANS administration was associated with similar mortality risk as those exposed to ANS 18 to 48 hours before delivery. Under the assumption of a causal relationship between timing of ANS and mortality, our simulations showed that if infants with no ANS prior to delivery received ANS 6 to 12 hours before delivery, their mortality was estimated to have been reduced by 51%. Furthermore, the administration of ANS was associated with a significant reduction in severe neonatal morbidity.

Our findings challenge current thinking about the optimal timing of ANS. Previously, ANS administered less than 24 hours before birth have been referred to as suboptimal,6,16 partial,12 or incomplete,9 suggesting poorer effectiveness at administration-to-birth intervals less than 24 hours. However, the categories used in previous studies appear to have hidden clinically important effects of ANS occurring within this period. In addition, given that most (77.9%) pregnant women in our study delivering within 24 hours of ANS only received 1 injection, significant effects may be achieved by a single ANS injection.19 In this context, we note with interest the recent statement by the National Institute for Health and Care Excellence Guideline Development Committee; taking account of the pharmacological mechanism of action of ANS, the committee suspects that any benefits from ANS would likely be transferred even if there was only a limited amount of time between administration and time of birth.

The underlying mechanisms for the rapid actions of ANS suggested herein are not fully understood. Cord blood concentrations of ANS peak 1 hour after administration to the mother and become undetectable 2 days after the last dose.14 While induction of many corticosteroid effects involve genomic interactions and therefore take time,14 nongenomic effects of corticosteroids have in more recent years also been discovered. These effects can be very rapid and occur within minutes.17,18 Nongenomic effects may contribute to findings in preterm lambs, demonstrating beneficial corticosteroid effects on pulmonary edema and blood pressure within 8 hours after administration and significant lung function improvement within 15 hours.16 In humans, fetal movements and heart variability increased significantly within 8 hours after ANS, possibly indicating fetal well-being or fetal stress enhancing maturation.15

Although the risk reduction was slower than that associated with survival—suggesting competing outcomes (mortality and morbidity) or that the underlying mechanisms may be different—an ANS administration-to-birth interval of 48 hours to 1 week was associated with a significantly reduced risk for severe neonatal brain injury. A lower risk of severe neonatal brain injury after ANS has previously been reported for patients at highest risk, ie, those born extremely preterm.22 A lower risk after a partial course of ANS has also been demonstrated.37 In these patients, the ANS-associated reduction in severe neonatal brain injury mediated protection against later neurodevelopmental impairment.22,37

We observed a 40% increased mortality in infants with an ANS administration-to-birth interval greater than 7 days compared with an interval of 1 to 7 days, a group representing 18.8% of all infants in our study. In 2015, Melamed et al6 reported similar findings using the Canadian Neonatal Network. Repeated courses of corticosteroids (betamethasone was the only drug tested) have been associated with a reduction in the incidence of respiratory distress syndrome and possibly also severity of neonatal lung disease.38 At 2-year to 3-year follow-up, there was no evidence of either significant benefit or harm with a repeated course of ANS in terms of rates of neurosensory disabilities, developmental delay, or growth failure.2,3,38 Follow-up in midchildhood demonstrated long-term safety.39

Strengths and Limitations

The strengths of our study include its prospective design, large size, and heterogeneous population including both tertiary and nontertiary centers all over Europe. This ensures generalizability to a wide range of settings. Case mix, mortality, and morbidity rates are within the same ranges as previously reported from other high-income countries.4 We had power and data in sufficient detail to perform adjusted analyses on timing of ANS and outcome at very short administration-to-birth intervals. The outcomes—infant survival and major neonatal morbidities—were robust and clinically highly relevant.

Our study also has limitations. Even though we excluded infants with malformations and infants born before 24 weeks’ GA, and even after adjusting for group differences presented in Table 1, residual confounding may have occurred, as the populations of women who delivered at various points after ANS administration may have been different. We investigated several outcomes, and multiple confidence intervals are reported in this article; caution should be applied when evaluating their joint statistical level. The EPICE database does not contain information on time of admission, so we could not determine admission-to-administration intervals. In addition, reasons for not treating pregnant women with ANS were not available, and we cannot exclude that withholding treatment may have occurred in some cases, especially at the lower end of GAs. However, we were able to adjust for a wide range of perinatal characteristics as well as factors reflecting management.

In our cohort, 7.0% of women received ANS but had no data on timing of administration; comparison of their characteristics suggests that these missing data may represent emergencies with suboptimal documentation. Some women had incomplete data on timing; for these patients, we used multiple imputation, which yielded results similar to complete case analysis. Our study was descriptive with no attempts in the
Conclusions

In conclusion, our results suggest significant health-promoting effects of ANS beginning just hours before delivery. This new knowledge encourages a more proactive management of women at risk for imminent preterm birth, which may help reduce infant mortality and severe neonatal brain injury. Our study also highlights that a large proportion of women remain at risk for very preterm birth more than 7 days after ANS and that their infants have increased morbidity and mortality. We suggest that future research areas should include testing optimal dosing (1 vs 2 doses) and dosing intervals of ANS. Given the suggestion of very rapid action, immediate postnatal corticosteroid rescue for very preterm infants unexposed to ANS could also be a topic for future research.

ARTICLE INFORMATION

Accepted for Publication: February 21, 2017.
Published Online: May 15, 2017.

Author Affiliations: Division of Pediatrics, Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden (Norman, Wilson); Department of Neonatal Medicine, Karolinska University Hospital, Stockholm, Sweden (Norman, Wilson); INSERM Joint Research Unit 1153, Obstetrical, Perinatal, and Pediatric Epidemiology Research Team (Epopé), Center for Epidemiology and Statistics Sorbonne Paris Cité, University Hospital Department Risks in Pregnancy, Paris Descartes University, Paris, France (Piedvache, Zeitlin); Department of Neonatology, Hvidovre University Hospital, Hvidovre, Denmark (Barth, Pryds); Department of Obstetrics, Hvidovre University Hospital, Hvidovre, Denmark (Huusom, Weber); Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden (Baronny); Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden (Baronny); Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York (Howell); Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York (Howell); University Paris Descartes and Department of Neonatal Medicine and Intensive Care Unit of Port-Royal, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France (Jarreau); Children’s Hospital, University Hospital, Philip University of Marburg, Marburg, Germany (Maier); Tallinn Children’s Hospital, Tallinn, Estonia (Toome); University of Tartu, Tartu, Estonia (Toome); Tartu University Hospital, University of Tartu, Tartu, Estonia (Varendi); Department of Neonatology, Radboud University Medical Center, Nijmegen, the Netherlands (Van Heijst); Research Unit of Perinatal Epidemiology, Clinical-Care and Management Innovation Research Area, Bambino Gesù Children’s Hospital, Rome, Italy (Cuttini); Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland (Mazela); Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal (Barros); Department of Neonatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium (Van Reempts); Study Centre for Perinatal Epidemiology Flanders, Brussels, Belgium (Van Reempts); Department of Health Sciences, University of Leicester, Leicester, England (Draper).

Author Contributions: Ms Piedvache and Zeitlin had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.


Group Information: In addition to the listed authors, the Effective Perinatal Intensive Care in Europe (EPICE) Research Group includes the following members: Study Centre for Perinatal Epidemiology, Brussels, Flanders, Belgium: Evelyne Martens, MSC; and Guy Martens; Department of Pediatrics, Hvidovre University Hospital, Hvidovre, Denmark: Asbjørn Hasselager, MD; INSERM Joint Research Unit 1153, Obstetrical, Perinatal, and Pediatric Epidemiology Research Team (Epopé), Center for Epidemiology and Statistics Sorbonne Paris Cité, University Hospital Department Risks in Pregnancy, Paris Descartes University, Paris, France: Pierre-Yves Ancel, MD, PhD; Béatrice Blondel, PhD; and Mercedes Bonet, MD, PhD; Division of Pediatrics 2, Bocage Hospital, INSERM CIE, Dijon University Hospital, Dijon University, Dijon, France: Antoine Burguet, MD, PhD; Department of Neonatology, Jeanne de Flandre Hospital, Lille University Hospital, France: Patrick Truffert, MD, PhD; Institute of Quality Assurance Hesse, Eschborn, Germany: Björn Misceiwitz, MD; Department of Obstetrics, University Hospital, Philippus University Marburg, Marburg, Germany: Stephan Schmidt, MD, DMSc; Children’s Hospital, University Hospital, University of Saarland, Saarbrücken, Germany: Ludvig Gortner, MD; Hospital Care Services, General Directorate for Health and Social Policies, Bologna, Emilia Romagna Region, Italy: Dante Barancioni, MD; Neonatal Intensive Care Unit, Department of Obstetrics and Pediatrics, Saint Maria Nova Hospital, Florence, Italy: Giancarlo Gargano, MD; Fatebenefratelli Hospital, Rome, Italy: Rocco Agostino, MD; Agency for Public Health of Lazio Region, Health Department, Rome, Italy: Domenico DiLallo, MD; and Francesco Franco, MSc; Maternal and Child Health Institute, Marche University and Salesi Hospital, Ancona, Italy: Virgilio Carnelli, MD; Perinatal Epidemiology, Clinical Care and Management Innovation Research Area, Bambino Gesù Children’s Hospital, Rome, Italy: Ileana Croc, MSc; Department of Neonatology, Wilhelmmina Children’s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands: Corrine Koopman-esseboem, MD, PhD; and Joppe Nijman, MD, PhD; Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland: Janusz Gadzienowski, MD, PhD; Department of Obstetrics and Gynecology, Santa Maria University Hospital, Faculty of Medicine, University of Lisbon, Lisbon, Portugal: Luis Mendes Graça, MD, PhD; Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Center, Lisbon, Portugal: Maria do Cau Machado, MD, PhD; Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal: Carina Rodrigues, MSc; and Teresa Rodrigues, MD, PhD; Department of Clinical Epidemiology, Predictive Medicine, and Public Health, University of Porto Medical School, Porto, Portugal: Teresa Rodrigues, MD, PhD; Department of Gynecology and Obstetrics, Centro Hospitalar São João, Porto, Portugal: Teresa Rodrigues, MD, PhD; Department of Health Sciences, University of Leicester, Leicester, England: Elaine Boyle, MBCHB, MD, PhD; and Brad N. Markelow, BSc, MSc, PhD; Newcastle University, Newcastle upon Tyne, England: Alan C. Fenton, MD.

Conflict of Interest Disclosures: None reported.

Funding/Support: The research received funding from grant agreement 259882 from the European Union Seventh Framework Program (2007-2013). Additional funding in France was provided by the French Institute of Public Health Research/Institute of Public Health and its partners, including the French Health Ministry, the National Institute of Health and Medical Research, the National Institute of Cancer, and the National Solidarity Fund for Autonomy, by grant ANR-11-EXPQ-O038 from the National Research Agency through the French Equipex Program of Investments in the Future, and by the PreeMUp Foundation, in Poland, by the 2012-2015 allocation of funds for international projects from the Polish Ministry of Science and Higher Education; and in Sweden, by regional agreement on medical training and clinical research between Stockholm County Council and Karolinska Institutet and by the Department of Neonatal Medicine at the Karolinska University Hospital.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or
Timing of Antenatal Corticosteroids for Preterm Birth Revisited

REFERENCES


